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Abstract: Intestinal microbiota-virus-host interaction has emerged as a key factor in mediating enteric
virus pathogenicity. With the aim of analyzing whether human gut bacteria improve the inefficient
replication of human rotavirus in mice, we performed fecal microbiota transplant (FMT) with healthy
infants as donors in antibiotic-treated mice. We showed that a simple antibiotic treatment, irrespective
of FMT, resulted in viral shedding for 6 days after challenge with the human rotavirus G1P[8]
genotype Wa strain (RVwa). Rotavirus titers in feces were also significantly higher in antibiotic-
treated animals with or without FMT but they were decreased in animals subject to self-FMT,
where a partial re-establishment of specific bacterial taxons was evidenced. Microbial composition
analysis revealed profound changes in the intestinal microbiota of antibiotic-treated animals, whereas
some bacterial groups, including members of Lactobacillus, Bilophila, Mucispirillum, and Oscillospira,
recovered after self-FMT. In antibiotic-treated and FMT animals where the virus replicated more
efficiently, differences were observed in gene expression of immune mediators, such as IL1β and
CXCL15, as well as in the fucosyltransferase FUT2, responsible for H-type antigen synthesis in
the small intestine. Collectively, our results suggest that antibiotic-induced microbiota depletion
eradicates the microbial taxa that restrict human rotavirus infectivity in mice.
Keywords: rotavirus; antibiotic; microbiota; mice; virus shedding
1. Introduction
Diarrheal disease is the second leading cause of death worldwide in children under
five years of age, accounting for around 525,000 deaths each year. Rotavirus (RV) is among
the predominant causes of non-bacterial acute gastroenteritis in infant and young children,
with an estimated 150,000 deaths per year, mostly in developing countries [1]. The gut is
a very complex ecosystem, with multiple interactions between the host immune system,
glycobiology, resident microbiota, and viruses responsible for gastroenteritis [2–5]. A link
between human RV infection and intestinal bacterial populations has been revealed from
analysis of the microbiota in population groups displaying different vaccine take after
inoculation with RV live vaccines [6,7]. However, the role of commensal microbiota in
RV infectivity is still controversial. Early evidences pointed towards a positive effect,
showing reduced RV infectivity in germ-free or antibiotic-treated mice [8]. Contrarily, some
microorganisms, including probiotic bacteria, directly interact with RV and potentially
block their binding to epithelial receptors, counteracting infection [9].
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RV attach to glycans of the histo-blood group antigen (HBGA) expressed in the gas-
trointestinal tract. In humans, fucosylation of O-linked HBGA at this location is controlled
by FUT2 and FUT3 gene expression, and it has been demonstrated that the glycosylation
patterns of those receptors could be altered by the action of specific commensal bacteria [10].
The main human RV genotype (G1P[8]) recognizes fucosylated HBGAs, such as H-type
1 [11], synthesized by FUT2 activity, and Lewis b antigens [12], synthesized by FUT3, but
these viruses show inefficient spread or no replication at all in the mouse model [13].
With the aim of obtaining a versatile animal model for human RV infection, we tested
whether engraftment of infant intestinal microbiota would permit G1P[8] RV infection
in the mouse model. We showed that a simple microbial ablation through antibiotics
was sufficient to promote human RV infection in mice, highlighting a role for intestinal
microbiota in suppressing these RVs in the murine model.
2. Materials and Methods
2.1. Rotavirus Stock Preparation
A human RVwa strain was produced as previously described [14] with modifications.
Briefly, 10 MA104-confluent 150 cm2 flasks (approximately 1.5 × 107 cells/flask) were
infected with Wa RV at a multiplicity of infection (MOI) of 0.1 and the flasks were kept
at 37 ◦C for one week. After infection the virus was pelleted at 100,000× g for 2 h in a
Himac R25ST-0507 rotor coupled to a Himac CR-30N× centrifuge. The pelleted virus
was resuspended in TNC (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM CaCl2) and
ultra-centrifuged in a sucrose gradient (30–70%) in TNC. The gradient was run in a SW41
rotor coupled to a Beckman L80 ultracentrifuge at 150,000× g for two hours. The band
containing RV was collected and the virus was finally recovered by pelleting in the SW41
rotor coupled to the Beckman L80 ultracentrifuge for 2 h at 150,000× g and resuspended in
TNC. After preparation the RV Wa stock was titrated by qPCR, as previously described [15].
2.2. Donor Microbiota Preparation
Stool samples from four healthy human infants between one and three months of age
were collected and resuspended in a solution consisting of 80%×-concentrated brain–heart
infusion (Pronadisa, Madrid, Spain), supplemented with 0.1% cysteine, and 20% of a
200 g/L skim milk (Scharlab, Barcelona, Spain) solution. This mixture was then diluted
1:2 (v/v) in the same medium and stored in aliquots at −80 ◦C. Mice fecal pellets from
the animal groups were collected before the experiments and preserved using the same
procedure.
2.3. Antibiotic Treatment and Microbiota Stool Transplant
Four groups of five C57BL/6J female 6 week-old mice were used in the present study.
Three groups were treated with an antibiotic cocktail composed of 1 g/L ampicillin, 1 g/L
metronidazole, 1 g/L neomycin, and 0.5 g/L vancomycin in drinking water, as previous
described with modifications [16]. To diminish intestinal microbiota load, the animals
were given the antibiotic-containing water ad libitum for three weeks and the antibiotic
cocktail was renewed every three days. To determine the number of viable bacteria in mice
stools, samples were collected at the beginning of the experiment and the day before RV
infection, and serially diluted in brain heart infusion supplemented with 0.1% cysteine. The
dilutions were plated in Wilkins–Chalgren medium containing 1.5% agar and incubated
in anaerobic conditions (AnaeroGen, Sigma, Madrid, Spain) at 37 ◦C for 48 h. Mice were
fed a standard diet until one week before fecal transplantation, when it was substituted by
purified-defined germ-free diet (AIN-93G, Envigo, Barcelona, Spain ).
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The control group was maintained without antibiotics. Twenty-four hours after
antibiotic treatment completion, two groups of mice were subjected to fecal material
transplantation (FMT), as previously described with modifications [17]. One group of
mice was transplanted with the preserved microbiota from the same group of mice before
antibiotic treatment (100 µL of prepared fecal material per mice for three consecutive days
through oral gavage). A second group of mice received a FMT using the same procedure
with a pool of bacteria from infant feces (100 µL of a pooled mix of four healthy infants for
three days through oral gavage).
2.4. Rotavirus Challenge
Six days after FMT the mice were orally inoculated with 1 × 1010 genome copy
equivalent (GCE) of RVwa in 100 µL of TNC. After RV dosing, the antibiotic-treated group
without FMT continued the drinking water antibiotic treatment, whereas in the FMT mice
groups, antibiotics were omitted from water from the day before microbiota transplant.
Stool samples were collected daily for 7 days and kept at −20 ◦C. The mice were euthanized
at 7 days post-infection (dpi) and the small intestine was removed and stored in RNAlater
(Sigma) at −80 ◦C for further analysis.
2.5. Quantification of Rotavirus from Stool Samples by RT-qPCR
We extracted RNA from mice stool samples using the NucleoSpin RNA Virus (Macherey-
Nagel, Duren, Germany) kit following the manufacturer’s instructions. The primers and
probe sequences utilized for RT-qPCR have previously been described [15]. Amplification of
RNA samples was performed with one-step TaqMan RT-qPCR using the RNA UltraSense
One-Step quantitative system (Thermo Fisher Scientific, Madrid, Spain). The standard curve
was generated by serial end-point dilution, amplifying 10-fold dilutions of the quantified
plasmid containing the RV target sequence by RT-qPCR in triplicates.
2.6. Quantification of Cytokine and Glycosyltransferase mRNA Expression Level
Then, 100 mg of tissue from the small intestine of infected mice were homogenized
in 1 mL of Trizol (Thermo Fisher Scientific) using a Polytron PT10-35 GT (Thermo Fisher
Scientific) at 16,000 rpm. After tissue disruption the RNA was purified following the
manufacturer’s instructions and the RNA finally resuspended in 50 µL of DEPC-treated
water. The RNA was treated with RNAse-free DNAse I (Thermo Fisher Scientific) to remove
the contaminant DNA and retro-transcribed to cDNA using the SuperScript III enzyme
(Thermo Fisher Scientific) and random primers following the manufacturer’s instructions.
The cDNA obtained was kept at −20 ◦C until use. Expression levels of genes encoding
cytokines IL1β, IL4, IL6, CXCL15, IL10, IL12, IL13, TNFα, IFNγ, and TLR2 were studied
in a LightCycler480 Instrument SW1.5 (Roche Life Science, Basel, Switzerland) and the
expression analysis performed with the Rest Software [18]. The expression level of GAPDH
and RPLPO housekeeping genes was used as reference. A list of primers employed can be
found in Supplementary Table S1.
Glycosyltransferase FUT2 gene expression was also analyzed by RT-qPCR. Primer and
probe preparation for the gene was purchased from Integrated DNA Technologies, Inc. (IDT,
assay ID: Mm.PT.58.50508299). The NZYSpeedy qPCR Probe Master Mix (NZY, Lisbon,
Portugal) was utilized. The qPCR was run in the StepOnePlus Real-Time PCR System
(Applied Biosystems) and expression analysis was performed with Rest Software [18],
using HPRT gene expression (assay ID: Mm.PT.39a.22214828) as a reference.
2.7. Microbiota Profiling in Mice Stool Samples
Total rDNA 16S in mice feces was quantified by qPCR as previously described [19].
To assess microbiota composition, DNA was extracted from mice fecal pellets obtained
prior to RVwa inoculation from all experimental groups with the Master Pure™ kit (Epicen-
tre), including a bead beater treatment with 0.5 g of 0.1 mm glass beads in the lysis step (Fast-
Prep 24-5G Homogenizer; MP Biomedicals, CA, USA), followed by final purification of the
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extracted DNA samples with mi-PCR Purification kit (Metabion, Planegg-Steinkirchen, Ger-
many). DNA was quantified with a Qubit 2.0 fluorometer (Invitrogen, Thermo Fisher Sci-
entific, Madrid, Spain). Bar-coded amplicons of the 16S rDNA V3–V4 region, multiplexed
using Nextera XT Index Kit, were subject to 2 × 300 bp paired-end run in a MiSeq-Illumina
platform (SCSIE, University of Valencia, Valencia, Spain). Data were demultiplexed using
Illumina bcl2fastq© program and reads were checked for quality, adapter trimmed and
filtered using AfterQC and FastQC v0.11.8 (http://www.bioinformatics.babraham.ac.uk,
accessed 10 May 2021) tools. QIIME software V1.9.1 [20] was used to analyze MiSeq
sequencing data, including forward and reverse reads joining, chimera removal, data
filtering, and taxonomic annotation. Chimeric sequences were removed from the reads
using the USEARCH 6.1 algorithm. Reads were clustered into operational taxonomic units
(OTUs) based on a 97% identity threshold value. Sequence were aligned to the Green-
genes core reference database (version 13.8) using PyNAST. Taxonomic assignment was
made using the UCLUST classifier. A total of 4,356,240 non-chimeric reads were obtained,
with a mean of 207,440 sequences per sample. Datasets were rarefied to the minimum
library size (43,791 reads) and normalized by total-sum scaling prior analysis with Ca-
lypso 8.84 (http://cgenome.net/calypso/ accessed 10 May 2021) and MicrobiomeAnalyst
(https://www.microbiomeanalyst.ca/ accessed 10 May 2021; [21] software pipelines.
3. Results
3.1. Mice with Depleted Microbiota and Transplanted with Human Feces Shed Wa Rotavirus for
6 Days
We reasoned that in the intestinal niche of infants where RV develop, the resident
microbiota determines infectivity. Then, we asked whether infection of RVwa (G1P[8])
in the mouse model could be improved by replacing its intestinal microbiota with the
microbiota of infants by FMT using antibiotic (Ab)-mediated microbiota ablation. In order
to answer this, C57BL/6J mice were treated with an antibiotic cocktail through drinking
water for three weeks. Bacterial counts in fecal pellets decreased from 6.3–9.7 × 1010 CFU/g
to no detectable counts (plating 10−1 dilutions), whereas they remained stable in the non-
treated control (4.9 × 1010 CFU/g), indicating an efficient depletion of the culturable gut
bacteria. Mice were then subject to FMT and orally dosed with the Wa strain. The virus
could be detected in the feces of control animals with a peak at one day post-infection
(dpi; 9.1 × 109 genome copy equivalent (GCE)/g feces), which rapidly dropped, with RV
being under the detection limit at dpi 4 (Figure 1). By the contrary, compared to control
animals, at dpi 1 viral shedding in Ab-treated mice and in mice subject to human FMT
(hFMT) was 23- and 16-fold higher (2.1 × 1011 GCE/g and 1.5 × 1011 GCE/g, respectively)
and remained until dpi 5–6, following the same evolution pattern and with values higher
than 109 GCE/g. The lower levels of RV detected in control animals and its faster clearance
were indicative of an inefficient replication, in contrast to the prolonged viral shedding in
Ab-treated mice and in the hFMT group. In mice receiving a self-FMT, partial restoration
of the restrictive replication of RVwa was evidenced, and virus shedding was detected at
levels similar to control at dpi 1, with no detectable viral shedding at dpi 4 (Figure 1).
3.2. Impact of Fecal Microbiota Transplant on Mouse Microbiota
The results of viral shedding pointed to microbiota changes by Ab treatment and
hFMT as responsible for RVwa infection permissiveness in mice. The treatment with
antibiotics significantly reduced the number of bacteria calculated by 16S rDNA qPCR
(Figure 2). Both the transplant from human feces and the self-transplant increased the
number of bacteria with no significant differences between them (Figure 2).
Biomedicines 2021, 9, 846 5 of 14
Biomedicines 2021, 9, x FOR PEER REVIEW 5 of 15 
 
 
Figure 1. Rotavirus Wa shedding in mice stool. GCE/g of stool are presented for control mice, Ab-
treated mice and mice subject to hFMT and self-FMT, respectively. The mice were followed for 6 
days and euthanized on day 7. The letters indicate statistically significant differences (p < 0.05) in 
the GCE between the groups (a, Ab vs. control; b, Ab vs. self-FMT; c, hFMT vs. control; d, hFMT vs. 
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stool. Ab, antibiotic; hFMT, human fecal microbiota transplantation; self-FMT, self-fecal microbiota 
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Figure 1. Rotavirus Wa shedding in mice stool. GCE/g of stool are presented for control mice, Ab-treated mice and mice
subject to hFMT and self-FMT, respectively. The mice were followed for 6 days and euthanized on day 7. The letters indicate
statistically significant differences (p < 0.05) in the GCE between the groups (a, Ab vs. control; b, Ab vs. self-FMT; c, hFMT
vs. control; d, hFMT vs. self-FMT). The error bars are standard deviations (n = 5). The limit of detection was 105 GCE/g of
stool. Ab, antibiotic; hFMT, human fecal microbiota transplantation; self-FMT, self-fecal microbiota transplantation.
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Figure 2. Total bacteria 16S DNA quantification by qPCR. The 16S DNA genomic copies/g of stool
are presented for control mice, Ab-treated mice and mice subject to self-FMT and hFMT, respectively.
Ab-treated mice had significantly lower amount of genome copies than the other three groups
(p < 0.02). No significant differences were found between the human and self-transplanted groups.
The microbiota composition in feces prior to RV challenge was determined by 16S
rDNA NGS, showing that bacterial richness and diversity was severely affected after the
different treatments (Figure 3A). Chao1 index was lowered in all groups compared to
control (microbial richness; p = 2.0365 × 10−12; F = 206.49, ANOVA) but was higher in
self-FMT animals. Diversity (Shannon index) was also lower (p = 1.8988 × 10−8; F = 57.299,
ANOVA), but was higher in the hFMT group compared to self-FMT group, indicating
uneven microbial distribution after treatments. In both types of analyses Ab treatment
resulted in lower α diversity. As expected, the three distinct treatments caused profound
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remodeling of the intestinal microbial profile and all groups could be differentiated in terms
of overall composition (Figure 3B,C). In mice treated with Ab, members of the phyla Firmi-
cutes and Proteobacteria, belonging to the genus Lactococcus and unidentified γ-Proteobacteria
















































Figure 3. Changes in intestinal bacterial composition in the mice groups. (A) Microbial α-diversity. Microbial richness
(Chao1) and diversity (Shannon) indexes are shown. (B) Relative abundance of bacterial taxa (family and genus levels)
found in the feces of the different mice groups. (C) Differences in microbial global composition after the different treatments.
A principal coordinate analysis (PCoA) of the Bray-Curtis dissimilarity indexes of samples is shown (PERMANOVA
F-value = 36.77; R2 = 0.8803; p < 0.001).
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The microbiota present in the pooled infant feces was not completely engrafted in
mice after hFMT (Figure 4), but these mice were characterized by elevated numbers of
Bacteroidetes and presence of members of the genus Megasphaera, a bacterial taxon that
was absent in the microbiota of untreated mice (Figure 5A). Genera, such as Bifidobacterium,
Adlercreutzia, Ruminococcus, Coprococcus, Turicibacter, Odoribacter, and Allobaculum, were
completely depleted after Ab treatment and they were not replenished by any FMT, includ-
ing self-FMT (Figure 5B). Although microbial engraftment was not completely successful
in the self-FMT group (differences in α and β diversity were obvious compared to con-
trol animals), bacteria belonging to Oscillospira, Lactobacillus, Mucispirillum, and Bilophila
were partially restored in mice via self-FMT (Figure 5C). In addition, in self-FMT animals
proportions of Akkermansia and Sutterella taxons were increased compared to control mice
(Figure 5D). In summary, low microbial richness and ablation of most representative taxa
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subject to hFMT. The panel (A) shows the relative abundance of bacteria at family level of the donor 
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expression levels did not differ between experimental groups and control animals, 
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IL1β and CXCL15 messenger levels were lower in the Ab and hFMT groups where human 
rotavirus replicated more efficiently. Expression of IL10, TLR2, and TNFα was also re-
duced in all groups compared to control. Finally, IFNγ expression was diminished in mice 
subject to both FMT treatments. Expression of the FUT2 gene, whose product is involved 
in α1,2-fucosylation during the synthesis of mucosal H type-1 antigen (fucosyl-α1,2-ga-
lactopyranosyl-β1,3-N-acetyl-glucopyranoside), one of the P[8] RV adhesin receptors, was 
downregulated in self-FMT animals. Interestingly, the FUT2 gene expression differed be-
tween both transplanted groups, having a higher expression (p = 0.003) in the group that 
received the human feces transplant (Figure 6). More interestingly, a significant negative 
correlation was found between the expression level of IL1β and the rotavirus shedding in 
feces at 2 dpi (Pearson r = −0.7203, p = 0.0005). More moderate correlations were also found 
with TLR2 (Pearson r = −0.5824, p = 0.0089) and TNFα (Pearson r = −0.4654, p = 0.0446). 
Figure 5. Bacterial genera showing differences between treatment groups. A LEfSe analysis was per-
formed to detect bacterial markers characteristic of each treatment condition. The different box-plots
represent abundance (log transformation of data normalized by total-sum scaling ×107) of bacterial
genera showing LDA scores >4. (A) Bacteria ugmented after hFMT; (B) Genera ablated or imin-
ished by Ab treatment; (C) Bacteria that were partially restored by self-FMT; (D) Bacteria augmented
after self-FMT; (E). Bacteria increased in Ab-group. Red, control animals; green, antibiotics-treated
animals; blue, self-FMT; magenta, hFMT.
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3.3. Immune and Epithelial Glycosylation Gene Expression in the Gut Associates with Human
Rotavirus Infection in Mice
Gene expression levels of a panel of cytokines and other innate immune system media-
tors including IL1β, IL4, IL6, CXCL15, IL10, IL12, IL13, IFNγ, TNFα, and TLR2 were studied
by RT-qPCR in the small intestine of mice at 7 dpi (Figure 6). IL6, IL12, and IL13 expression
levels did not differ between experimental groups and control animals, whereas a down-
regulation effect was generally observed in the remaining tested genes. IL1β and CXCL15
messenger levels were lower in the Ab and hFMT groups where human rotavirus repli-
cated more efficiently. Expression of IL10, TLR2, and TNFα was also reduced in all groups
compared to control. Finally, IFNγ expression was diminished in mice subject to both FMT
treatments. Expression of the FUT2 gene, whose product is involved in α1,2-fucosylation
during the synthesis of mucosal H type-1 antigen (fucosyl-α1,2-galactopyranosyl-β1,3-
N-acetyl-glucopyranoside), one of the P[8] RV adhesin receptors, was downregulated in
self-FMT animals. Interestingly, the FUT2 gene expression differed between both trans-
planted groups, having a higher expression (p = 0.003) in the group that received the
human feces transplant (Figure 6). More interestingly, a significant negative correlation
was found between the expression level of IL1β and the rotavirus shedding in feces at 2 dpi
(Pearson r = −0.7203, p = 0.0005). More moderate correlations were also found with TLR2
(Pearson r = −0.5824, p = 0.0089) and TNFα (Pearson r = −0.4654, p = 0.0446).
Biomedicines 2021, 9, x FOR PEER REVIEW 10 of 15 
 
 
Figure 6. Differences in gene expression in the small intestine of infected mice. Expression of immune system mediators 
(IL1β, IL4, IL6, CXCL15, IL10, IL12, IL13, IFNγ, TNFα, and TLR2) and fucosyltransferase 2 (FUT2) was determined by RT-
qPCR in mice from the different groups at 7 dpi (n = 5). The level of significance is indicated for control mice (* p < 0.05). 
4. Discussion 
Gut microbiota has emerged as a pivotal player in enteric virus-host interactions, and 
has been shown or hypothesized to have positive, as well as negative effects on viral in-
fectivity, mediated by different mechanisms [2–5]. Given the lack of an efficient mouse 
model to replicate relevant human RV strains [13], we studied whether mice could be 
infected with RVwa after an infant gut microbiota engraftment. This RV strain has been 
used as a model for human RV studies and has special relevance because it carries the P[8] 
VP4 genotype, which is responsible for around 90% of infections [22]. An available in vivo 
model of replication would therefore be desirable, yet its infectivity in small animal mod-
els is not satisfactory. 
In our study, RVwa infection could not be linked to hFMT, ruling out the possibility 
that human intestinal microbiota mediates RVwa infectivity in mice. Nonetheless, we 
show that independently of subsequent hFMT, simple gut bacteria depletion through an-
tibiotic treatment dramatically increased the replication capacity of the RVwa strain in 
this host. Altered intestinal bacterial loads in the mice do not account for the differences 
in RVwa replication, as no differences were found in bacterial numbers in the feces from 
groups that substantially differed in RVwa infection. It has been discussed that variations 
in the microbiome of experimental animals at different laboratories may affect mice phe-
notypes, which can be at the basis of reproducibility issues [23]. This situation would have 
minor effects in our case, as we showed that the sole fact of depleting the microbiota with 
Figure 6. Differences in gene expression in the small intestine of infected mice. Expression of immune system mediators
(IL1β, IL4, IL6, CXCL15, IL10, IL12, IL13, IFNγ, TNFα, and TLR2) and fucosyltransferase 2 (FUT2) was determined by
RT-qPCR in mice from the different groups at 7 dpi (n = 5). The level of significance is indicated for control mice (* p < 0.05).
Biomedicines 2021, 9, 846 10 of 14
4. Discussion
Gut microbiota has emerged as a pivotal player in enteric virus-host interactions,
and has been shown or hypothesized to have positive, as well as negative effects on viral
infectivity, mediated by different mechanisms [2–5]. Given the lack of an efficient mouse
model to replicate relevant human RV strains [13], we studied whether mice could be
infected with RVwa after an infant gut microbiota engraftment. This RV strain has been
used as a model for human RV studies and has special relevance because it carries the P[8]
VP4 genotype, which is responsible for around 90% of infections [22]. An available in vivo
model of replication would therefore be desirable, yet its infectivity in small animal models
is not satisfactory.
In our study, RVwa infection could not be linked to hFMT, ruling out the possibility
that human intestinal microbiota mediates RVwa infectivity in mice. Nonetheless, we show
that independently of subsequent hFMT, simple gut bacteria depletion through antibiotic
treatment dramatically increased the replication capacity of the RVwa strain in this host.
Altered intestinal bacterial loads in the mice do not account for the differences in RVwa
replication, as no differences were found in bacterial numbers in the feces from groups
that substantially differed in RVwa infection. It has been discussed that variations in the
microbiome of experimental animals at different laboratories may affect mice phenotypes,
which can be at the basis of reproducibility issues [23]. This situation would have minor
effects in our case, as we showed that the sole fact of depleting the microbiota with
antibiotics allowed RVwa replication. Our data suggest that endogenous mouse microbiota
restricts RVwa replication, which is in opposition to results obtained with the murine RV
EC strain, where Ab treatment had negative effects on viral entry, delaying and decreasing
infectivity in both adult (40% reduction in viral shedding) and neonatal (34% reduction in
diarrhea incidence) murine models [8]. However, recent research also points to a protective
role for the microbiota during murine RV (strain EDIM) infection, by demonstrating high
susceptibility to RV infection in Ab-treated and germ-free animals and highlighting a role
of microbiota-induced IL22 expression as an anti-viral mediator [24].
The importance of the microbiota in establishing an appropriate anti-viral immune
response has been noted [25,26]. Exacerbated systemic infection by several enteric and
non-enteric viruses was observed in Ab-treated mice, including vesicular stomatitis and
influenza virus [27], murine gamma herpesvirus [28], respiratory syncytial virus [29], en-
cephalomyocarditis virus [30], and West Nile, Dengue, and Zika viruses [31]. In some cases,
microbiota depletion has been linked to a defective innate immune response characterized
by low levels of type I IFN expression (IFNβ), which hampered the ability to mount an
effective anti-viral macrophage response [27,29]. In our experiments, antibiotic treatment
generally resulted in reduced expression of inflammatory mediators in the small intestine,
although no IFNβ expression could be detected in the whole tissue (data not shown). We
found that IL10 and TNFα displayed reduced expression in microbiota-depleted animals
and that IFNγ expression was also lower in FMT animals. These are important mediators
of immune response to infections, including RV, in which studies have previously reported
increased expression after infection in a mouse model [32,33]. Accordingly, although germ-
free mice show delayed infection with EC RV, viral clearance in this model was found to
last substantially longer, probably reflecting an immature intestinal immune system [8].
IL1β expression was lowered in Ab and hFMT groups and negatively correlated with
viral shedding. This cytokine plays a major role in early inflammatory response against
pathogens and its level is increased during RV infection in children [34]. Therefore, reduced
IL10, IL1β, TNFα, and IFNγ are likely to be beneficial for viral replication. TLR2, whose
expression was lowered in the Ab-treated groups, has been linked to the protective effect
of lactobacilli towards RV infection in animal models [35,36]. We also studied the associa-
tion between RV infection and FUT2. It was previously shown that specific members of
the gut microbiota, such as Bacteroides thetaiotaomicron, Bacteroides fragilis, and segmented
filamentous bacteria (SFB) are able to influence the pattern of mucosal glycosylation by
inducing epithelial FUT2 expression [10,37], which encodes the enzyme responsible for
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H-type antigen synthesis, the target for binding of RV P[8] adhesin [11]. We showed that
FUT2 expression in the small intestine was only reduced in self-FMT animals. Lack of
intestinal microbiota generally results in downregulation of FUT2 [37], and it is not known
how diminished FUT2 levels could affect RVwa infection in mice, especially given that
another entry mediator of P[8] RV, the Lewis b antigen [12], is not produced in this host.
A recent report shows that virulent RVwa (a strain serially passed in gnotobiotic pigs)
infection in porcine enteroids is enhanced by the presence of H antigen [38], but the role of
HBGA in infection in mice has yet to be determined.
The limited RVwa infection found in self-FMT animals suggests that specific microbial
taxa not implanted after hFMT are implicated in RV exclusion. Although self-FMT did
not restore the original microbiota of mice, several bacterial taxa with a potential role
in RVwa restriction were partially restored: Mucispirillum is a strict anaerobe typically
found in the murine intestinal tract, where it is intimately linked to the mucosal layer
and participates in inflammatory processes [39] and is also involved in excluding several
pathogenic bacteria [40]; Oscillospira is another anaerobe from the grastrointestinal tract,
and, although it has never been cultivated, evidence indicates its relevance to human
health [41]; Bilophila, which comprises the single species Biliophila wadsworthia, has been
linked to intestinal inflammation in mice [42]; and finally, lactobacilli are well-known
probiotic bacteria that have been shown to diminish RV-induced diarrhea in humans [43]
and reduce RV infection in both in vitro and in vivo models [44,45].
A recent study showed that members of the murine intestinal microbiota such as SFB
belonging to Candidatus Arthromitus are responsible for inhibiting murine RV EC strain
infection [46]. Thus, Ab elimination of SFB could explain Ab-treated mice tolerance to
RVwa infection. However, SFB were not found in our microbiota analysis and the model
where they were implicated in resistance to the murine RV strain EC used immunosup-
pressed Rag1-KO mice, which are defective in B and T lymphocytes. However, Candidatus
Arthromitus was not able to stably colonize normal mice [46]. Nevertheless, the idea that
some bacterial taxa, such as those re-established after self-FMT or others, could mediate
RVwa exclusion in mice is still attractive. Such a category of bacteria has been identified
and the anti-viral mechanisms behind them disclosed in some cases. As examples, oral
dosing of Blautia coccoides in Ab-mice restored the capacity of macrophages to induce IFNβ
and promoted protection against encephalomyocarditis virus systemic infection [30], and,
likewise, lipo-oligosaccharides from the outer membrane of Bacteroides and microbial
metabolism-derived acetate were involved in triggering an IFNβ response that prevented
vesicular stomatitis virus and influenza virus [27] and respiratory syncytial virus [29]
infection in mice, respectively.
RVwa permissiveness in Ab-treated mice could also derive from depletion of one
or various of the many microbial taxa affected by this treatment but not restored by self-
FMT. As an example, Ruminococcus practically disappeared after Ab administration. These
bacteria were correlated with low anti-RV IgA titers in human saliva of healthy subjects [47],
have recently been characterized as microorganisms physically interacting with RV in the
stools of children suffering P[8] RV-induced diarrhea, and reduced RVwa infectivity in
Caco-2 cell cultures [9]. Bifidobacterium, another relevant genus of probiotic bacteria with
proven anti-RV properties [45,48] was also eradicated by antibiotics.
Alternative mechanisms by which bacteria could mediate RV protection include direct
interaction of RV virions with bacteria, as hypothesized for SFB [46]. These interactions
have been evidenced in in vitro experiments for a number of bacterial strains [32,49].
Species such as Ruminococcus gauvreauii [9] and others [50] express HBGA-like substances
on their surface which are binding targets for RV. HBGAs act as virion stabilizers that
promote bacteria-assisted binding and enhance infection in some enteric viruses, such
as norovirus (NoV) and poliovirus [51–53] but can mediate virus sequestration on the
bacterial surface, which could prevent virus from binding to target cells.
The mechanisms underlying RVwa development in antibiotic-treated mice are as yet
unknown, but our results suggest either that natural mouse resistance to RVwa infection is
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triggered by indigenous mouse commensals that cannot be substituted by other human
intestinal bacteria, or, alternatively, that the equivalent human microorganisms cannot be
implanted in the mouse by simple FMT. Further characterization of the factors mediating
RV replication in Ab-treated mice is needed. Nonetheless, this in vivo infection model
may constitute a valuable tool to investigate the biology of RV. Identifying the bacteria
responsible for human RV restriction in mice will further understanding of the relationship
established between RV and intestinal commensals.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/biomedicines9070846/s1, Table S1: primers used for qPCR in the present study.
Author Contributions: Conceptualization, J.R.-D., J.B., V.M., R.G.-R., C.M., A.R.-d.-C., M.J.Y.;
Methodology, R.G.-R., C.S.-B., A.R.-d.-C., C.M., S.V.-V., V.M.; Writing–Original Draft Preparation,
J.R.-D., V.M.; Review and Editing, A.R.-d.-C., J.B., M.J.Y., C.M., R.G.-R., C.S.-B.; Project Administration
J.R.-D.; Funding Acquisition, J.R.-D., M.J.Y. All authors have read and agreed to the published version
of the manuscript.
Funding: This research was funded by Spanish Government (Ministerio de Economía y Competi-
tividad) grants AGL2017-84165-C2-1-R to MJY, AGL2017-84165-C2-2-R to JRD. The study was also
supported by Valencian Government grant IDIFEDER/2018/056 and by European FEDER founds.
RGR is the recipient of a postdoctoral grant from the Valencian Government (APOST/2017/037).
CSB is the recipient of a FPI predoctoral grant from the Spanish Government (RE2018-083315). SVV
is the recipient of a predoctoral grant from the Valencian Government (ACIF/2016/437).
Institutional Review Board Statement: All experiments using mice were conducted at the Animal
Production and Experimentation Service of the University of Valencia following national and in-
ternational regulations. The procedures were approved by Ethics Committee for Animal Welfare
and by the “Dirección General de Agricultura, Ganadería y Pesca” of the “Generalitat Valenciana”,
file number 2018/VSC/PEA/0181 approved the 19 December 2018. Use of human stool samples
was approved by the Human Research Ethics Committee of the University of Valencia (registration
number H154401046838) and written informed consent was obtained from a parent of each subject.
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: The raw sequencing fastq files were deposited in the SRA repository
(http://www.ncbi.nlm.nih.gov/sra accessed 1 July 2021) under Bioproject ID PRJNA706108.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Wang, H.; Naghavi, M.; Allen, C.; Barber, R.M.; Bhutta, Z.A.; Carter, A.; Casey, D.C.; Charlson, F.J.; Chen, A.Z.; Coates, M.M.; et al.
Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015:
A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016, 388, 1459–1544. [CrossRef]
2. Monedero, V.; Collado, M.C.; Rodríguez-Díaz, J. Therapeutic opportunities in intestinal microbiota-virus interactions. Trends
Biotechnol. 2018, 36, 645–648. [CrossRef] [PubMed]
3. Monedero, V.; Buesa, J.; Rodríguez-Díaz, J. The interactions between host glycobiology, bacterial microbiota, and viruses in the
gut. Viruses 2018, 10, 96. [CrossRef] [PubMed]
4. Kim, A.H.J.; Hogarty, M.P.; Harris, V.C.; Baldridge, M.T. The complex interactions between rotavirus and the gut microbiota.
Front. Cell. Infect. Microbiol. 2021, 10, 820. [CrossRef] [PubMed]
5. Roth, A.N.; Grau, K.R.; Karst, S.M. Diverse mechanisms underlie enhancement of enteric viruses by the mammalian intestinal
microbiota. Viruses 2019, 11, 760. [CrossRef] [PubMed]
6. Harris, V.; Ali, A.; Fuentes, S.; Korpela, K.; Kazi, M.; Tate, J.; Parashar, U.; Wiersinga, W.J.; Giaquinto, C.; de Weerth, C.; et al.
Rotavirus vaccine response correlates with the infant gut microbiota composition in Pakistan. Gut Microbes 2018, 9, 93–101.
[CrossRef] [PubMed]
7. Harris, V.C.; Armah, G.; Fuentes, S.; Korpela, K.E.; Parashar, U.; Victor, J.C.; Tate, J.; de Weerth, C.; Giaquinto, C.; Wiersinga, W.J.;
et al. Significant correlation between the infant gut microbiome and rotavirus vaccine response in rural Ghana. J. Infect. Dis. 2017,
215, 34–41. [CrossRef] [PubMed]
8. Uchiyama, R.; Chassaing, B.; Zhang, B.; Gewirtz, A.T. Antibiotic treatment suppresses rotavirus infection and enhances specific
humoral immunity. J. Infect. Dis. 2014, 210, 171–182. [CrossRef]
Biomedicines 2021, 9, 846 13 of 14
9. Gozalbo-Rovira, R.; Rubio-Del-campo, A.; Santiso-Bellón, C.; Vila-Vicent, S.; Buesa, J.; Delgado, S.; Molinero, N.; Margolles, A.;
Yebra, M.J.; Collado, M.C.; et al. Interaction of intestinal bacteria with human rotavirus during infection in children. Int. J. Mol.
Sci. 2021, 22, 1010. [CrossRef]
10. Goto, Y.; Uematsu, S.; Kiyono, H. Epithelial glycosylation in gut homeostasis and inflammation. Nat. Immunol. 2016, 17, 1244–1251.
[CrossRef]
11. Gozalbo-Rovira, R.; Ciges-Tomas, J.R.; Vila-Vicent, S.; Buesa, J.; Santiso-Bellón, C.; Monedero, V.; Yebra, M.J.; Marina, A.;
Rodríguez-Díaz, J. Unraveling the role of the secretor antigen in human rotavirus attachment to histo-blood group antigens. PLoS
Pathog. 2019, 15, e1007865. [CrossRef] [PubMed]
12. Xu, S.; Ahmed, L.U.; Stuckert, M.R.; McGinnis, K.R.; Liu, Y.; Tan, M.; Huang, P.; Zhong, W.; Zhao, D.; Jiang, X.; et al. Molecular
basis of P[II] major human rotavirus VP8* domain recognition of histo-blood group antigens. PLoS Pathog. 2020, 16, e1008386.
[CrossRef] [PubMed]
13. Ramig, R.F. The effects of host age, virus dose, and virus strain on heterologous rotavirus infection of suckling mice. Microb.
Pathog. 1988, 4, 189–202. [CrossRef]
14. Arnold, M.; Patton, J.T.; McDonald, S.M. Culturing, storage, and quantification of rotaviruses. Curr. Protoc. Microbiol. 2009, 15.
[CrossRef]
15. Jothikumar, N.; Kang, G.; Hill, V.R. Broadly reactive TaqMan®assay for real-time RT-PCR detection of rotavirus in clinical and
environmental samples. J. Virol. Methods 2009, 155, 126–131. [CrossRef]
16. Rakoff-Nahoum, S.; Paglino, J.; Eslami-Varzaneh, F.; Edberg, S.; Medzhitov, R. Recognition of commensal microflora by toll-like
receptors is required for intestinal homeostasis. Cell 2004, 118, 229–241. [CrossRef] [PubMed]
17. Rubio-Del-Campo, A.; Gozalbo-Rovira, R.; Moya-Gonzálvez, E.M.; Alberola, J.; Rodríguez-Díaz, J.; Yebra, M.J. Infant gut
microbiota modulation by human milk disaccharides in humanized microbiome mice. Gut Microbes 2021, 13, 1–20. [CrossRef]
18. Pfaffl, M.W.; Horgan, G.W.; Dempfle, L. Relative expression software tool (REST) for group-wise comparison and statistical
analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002, 30, e36. [CrossRef]
19. Rubio-Del-Campo, A.; Alcántara, C.; Collado, M.C.; Rodríguez-Díaz, J.; Yebra, M.J. Human milk and mucosa-associated
disaccharides impact on cultured infant fecal microbiota. Sci. Rep. 2020, 10, 1–12.
20. Caporaso, J.G.; Kuczynski, J.; Stombaugh, J.; Bittinger, K.; Bushman, F.D.; Costello, E.K.; Fierer, N.; Peña, A.G.; Goodrich, J.K.;
Gordon, J.I.; et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 2010, 7, 335–336.
[CrossRef]
21. Chong, J.; Liu, P.; Zhou, G.; Xia, J. Using MicrobiomeAnalyst for comprehensive statistical, functional, and meta-analysis of
microbiome data. Nat. Protoc. 2020, 15, 799–821. [CrossRef]
22. Pérez-Ortín, R.; Vila-Vicent, S.; Carmona-Vicente, N.; Santiso-Bellón, C.; Rodríguez-Díaz, J.; Buesa, J. Histo-blood group antigens
in children with symptomatic rotavirus infection. Viruses 2019, 11, 339. [CrossRef] [PubMed]
23. Witjes, V.M.; Boleij, A.; Halffman, W. Reducing versus embracing variation as strategies for reproducibility: The microbiome of
laboratory mice. Animals 2020, 10, 2415. [CrossRef]
24. Schnepf, D.; Hernandez, P.; Mahlakõiv, T.; Crotta, S.; Sullender, M.E.; Peterson, S.T.; Ohnemus, A.; Michiels, C.; Gentle, I.;
Dumoutier, L.; et al. Rotavirus susceptibility of antibiotic-treated mice ascribed to diminished expression of interleukin-22 2.
bioRxiv 2021. [CrossRef]
25. Li, N.; Ma, W.T.; Pang, M.; Fan, Q.L.; Hua, J.L. The commensal microbiota and viral infection: A comprehensive review. Front.
Immunol. 2019, 10, 1551. [CrossRef]
26. Abt, M.C.; Osborne, L.C.; Monticelli, L.A.; Doering, T.A.; Alenghat, T.; Sonnenberg, G.F.; Paley, M.A.; Antenus, M.; Williams,
K.L.; Erikson, J.; et al. Commensal Bacteria Calibrate the Activation Threshold of Innate Antiviral Immunity. Immunity 2012, 37,
158–170. [CrossRef]
27. Stefan, K.L.; Kim, M.V.; Iwasaki, A.; Kasper, D.L. Commensal microbiota modulation of natural resistance to virus infection. Cell
2020, 183, 1312–1324. [CrossRef] [PubMed]
28. Yaron, J.R.; Ambadapadi, S.; Zhang, L.; Chavan, R.N.; Tibbetts, S.A.; Keinan, S.; Varsani, A.; Maldonado, J.; Kraberger, S.; Tafoya,
A.M.; et al. Immune protection is dependent on the gut microbiome in a lethal mouse gammaherpesviral infection. Sci. Rep. 2020,
10, 1–13. [CrossRef] [PubMed]
29. Antunes, K.H.; Fachi, J.L.; de Paula, R.; da Silva, E.F.; Pral, L.P.; dos Santos, A.Á.; Dias, G.B.M.; Vargas, J.E.; Puga, R.; Mayer,
F.Q.; et al. Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon
response. Nat. Commun. 2019, 10, 1–17. [CrossRef]
30. Yang, X.-L.; Wang, G.; Xie, J.-Y.; Li, H.; Liu, W.; Zhu, S.J. The intestinal microbiome primes host innate immunity against enteric
virus 1 systemic infection through type I interferon 2. Res. Sq. 2021, 12, e00366-21.
31. Thackray, L.B.; Handley, S.A.; Gorman, M.J.; Poddar, S.; Bagadia, P.; Briseño, C.G.; Theisen, D.J.; Tan, Q.; Hykes, B.L.; Lin, H.; et al.
Oral antibiotic treatment of mice exacerbates the disease severity of multiple flavivirus infections. Cell Rep. 2018, 22, 3440–3453.
[CrossRef]
32. Kandasamy, S.; Vlasova, A.N.; Fischer, D.; Kumar, A.; Chattha, K.S.; Rauf, A.; Shao, L.; Langel, S.N.; Rajashekara, G.; Saif, L.J.
Differential Effects of Escherichia coli Nissle and Lactobacillus rhamnosus Strain GG on Human Rotavirus Binding, Infection,
and B Cell Immunity. J. Immunol. 2016, 196, 1780–1789. [CrossRef]
Biomedicines 2021, 9, 846 14 of 14
33. Zhang, Z.; Xiang, Y.; Li, N.; Wang, B.; Ai, H.; Wang, X.; Huang, L.; Zheng, Y. Protective effects of Lactobacillus rhamnosus GG
against human rotavirus-induced diarrhoea in a neonatal mouse model. Pathog. Dis. 2013, 67, 184–191. [CrossRef] [PubMed]
34. Jiang, B.; Snipes-Magaldi, L.; Dennehy, P.; Keyserling, H.; Holman, R.C.; Bresee, J.; Gentsch, J.; Glass, R.I. Cytokines as mediators
for or effectors against rotavirus disease in children. Clin. Diagn. Lab. Immunol. 2003, 10, 995–1001. [CrossRef]
35. Kadooka, Y.; Tominari, K.; Sakai, F.; Yasui, H. Prevention of rotavirus-induced diarrhea by preferential secretion of IgA in breast
milk via maternal administration of lactobacillus gasseri SBT2055. J. Pediatr. Gastroenterol. Nutr. 2012, 55, 66–71. [CrossRef]
[PubMed]
36. Wen, K.; Azevedo, M.S.P.; Gonzalez, A.; Zhang, W.; Saif, L.J.; Li, G.; Yousef, A.; Yuan, L. Toll-like receptor and innate cytokine
responses induced by lactobacilli colonization and human rotavirus infection in gnotobiotic pigs. Vet. Immunol. Immunopathol.
2009, 127, 304–315. [CrossRef] [PubMed]
37. Lin, B.; Saito, M.; Sakakibara, Y.; Hayashi, Y.; Yanagisawa, M.; Iwamori, M. Characterization of three members of murine α1,
2-fucosyltransferases: Change in the expression of the Se gene in the intestine of mice after administration of microbes. Arch.
Biochem. Biophys. 2001, 388, 207–215. [CrossRef] [PubMed]
38. Guo, Y.; Candelero-Rueda, R.A.; Saif, L.J.; Vlasova, A.N. Infection of porcine small intestinal enteroids with human and pig
rotavirus A strains reveals contrasting roles for histo-blood group antigens and terminal sialic acids. PLoS Pathog. 2021, 17,
e1009237. [CrossRef] [PubMed]
39. Loy, A.; Pfann, C.; Steinberger, M.; Hanson, B.; Herp, S.; Brugiroux, S.; Gomes Neto, J.C.; Boekschoten, M.V.; Schwab, C.; Urich, T.;
et al. Lifestyle and Horizontal Gene Transfer-Mediated Evolution of Mucispirillum schaedleri, a Core Member of the Murine Gut
Microbiota. mSystems 2017, 2, e00171-16. [CrossRef]
40. Herp, S.; Brugiroux, S.; Garzetti, D.; Ring, D.; Jochum, L.M.; Beutler, M.; Eberl, C.; Hussain, S.; Walter, S.; Gerlach, R.G.; et al.
Mucispirillum schaedleri Antagonizes Salmonella Virulence to Protect Mice against Colitis. Cell Host Microbe 2019, 25, 681–694.
[CrossRef]
41. Konikoff, T.; Gophna, U. Oscillospira: A Central, Enigmatic Component of the Human Gut Microbiota. Trends Microbiol. 2016, 24,
523–524. [CrossRef]
42. Natividad, J.M.; Lamas, B.; Pham, H.P.; Michel, M.L.; Rainteau, D.; Bridonneau, C.; Da Costa, G.; Van Hylckama Vlieg, J.; Sovran,
B.; Chamignon, C.; et al. Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice. Nat. Commun.
2018, 9, 1–15. [CrossRef] [PubMed]
43. Di, J.B.; Gai, Z.T. Protective efficacy of probiotics on the treatment of acute rotavirus diarrhea in children: An updated meta-
analysis. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 9675–9683. [PubMed]
44. Thompson, A.; Van Moorlehem, E.; Aich, P. Probiotic-induced priming of innate immunity to protect against rotaviral infection.
Probiotics Antimicrob. Proteins 2010, 2, 90–97. [CrossRef] [PubMed]
45. Vlasova, A.N.; Chattha, K.S.; Kandasamy, S.; Liu, Z.; Esseili, M.; Shao, L.; Rajashekara, G.; Saif, L.J. Lactobacilli and bifidobacteria
promote immune homeostasis by modulating innate immune responses to human rotavirus in neonatal gnotobiotic pigs. PLoS
ONE 2013, 8, e76962. [CrossRef] [PubMed]
46. Shi, Z.; Zou, J.; Zhang, Z.; Zhao, X.; Noriega, J.; Zhang, B.; Zhao, C.; Ingle, H.; Bittinger, K.; Mattei, L.M.; et al. Segmented
filamentous bacteria prevent and cure rotavirus infection. Cell 2019, 179, 644–658. [CrossRef] [PubMed]
47. Rodriguez-Diaz, J.; Garcia-Mantrana, I.; Vila-Vicent, S.; Gozalbo-Rovira, R.; Buesa, J.; Monedero, V.; Collado, M.C. Relevance of
secretor status genotype and microbiota composition in susceptibility to rotavirus and norovirus infections in humans. Sci. Rep.
2017, 7, 1–10.
48. Kawahara, T.; Makizaki, Y.; Oikawa, Y.; Tanaka, Y.; Maeda, A.; Shimakawa, M.; Komoto, S.; Moriguchi, K.; Ohno, H.; Taniguchi,
K. Oral administration of Bifidobacterium bifidum G9-1 alleviates rotavirus gastroenteritis through regulation of intestinal
homeostasis by inducing mucosal protective factors. PLoS ONE 2017, 12, e0173979. [CrossRef]
49. Salminen, S.; Nybom, S.; Meriluoto, J.; Collado, M.C.; Vesterlund, S.; El-Nezami, H. Interaction of probiotics and pathogens—
Benefits to human health? Curr. Opin. Biotechnol. 2010, 21, 157–167. [CrossRef]
50. Almand, E.A.; Moore, M.D.; Outlaw, J.; Jaykus, L.-A. Human norovirus binding to select bacteria representative of the human gut
microbiota. PLoS ONE 2017, 12, e0173124. [CrossRef]
51. Jones, M.K.; Watanabe, M.; Zhu, S.; Graves, C.L.; Keyes, L.R.; Grau, K.R.; Gonzalez-Hernandez, M.B.; Iovine, N.M.; Wobus, C.E.;
Vinje, J.; et al. Enteric bacteria promote human and mouse norovirus infection of B cells. Science 2014, 346, 755–759. [CrossRef]
[PubMed]
52. Kuss, S.K.; Best, G.T.; Etheredge, C.A.; Pruijssers, A.J.; Frierson, J.M.; Hooper, L.V.; Dermody, T.S.; Pfeiffer, J.K. Intestinal
microbiota promote enteric virus replication and systemic pathogenesis. Science 2011, 334, 249–252. [CrossRef] [PubMed]
53. Li, D.; Breiman, A.; le Pendu, J.; Uyttendaele, M. Binding to histo-blood group antigen-expressing bacteria protects human
norovirus from acute heat stress. Front. Microbiol. 2015, 6, 659. [CrossRef] [PubMed]
